Effects of Rooibos Tea Extract on Antigen-specific Antibody Production and Cytokine Generation in Vitro and in Vivo.

DOI Web Site Web Site PubMed 被引用文献4件 参考文献42件
  • KUNISHIRO Kazuyoshi
    Department of Immunochemistry, Faculty of Pharmaceutical Sciences, Okayama University
  • TAI Akihiro
    Department of Immunochemistry, Faculty of Pharmaceutical Sciences, Okayama University
  • YAMAMOTO Itaru
    Department of Immunochemistry, Faculty of Pharmaceutical Sciences, Okayama University

この論文をさがす

抄録

Rooibos tea contains a large amount of flavonoids and acts as a potent antioxidant. In this study, we examined the effects of Rooibos tea extract on antigenspecific antibody production and cytokine generation in vitro and in vivo. The primary in vitro anti-ovalbumin (anti-OVA) or sheep red blood cell (SRBC) antibody production in murine splenocytes was markedly stimulated by the addition of the tea extract at concentrations of 1-100 μg/ml. On the other hand, a nonspecific antibody response elicited with lipopolysaccharide (LPS) in purified splenic B-cells was not modified by the extract. Rooibos tea extract caused an increase in the generation of interleukin 2 (IL-2) both in OVA- and anti-CD3-primed splenocytes at concentrations ranging from 10 μg/ml to 1000 μg/ml. In contrast, this tea extract suppressed the generation of interleukin 4 (IL-4) in OVA-primed splenocytes. Moreover, the reduction of OVA-induced antibody production in serum of the cyclosporin A (CyA)-treated rats can be significantly restored and the IL-2 generation in murine splenocytes was stimulated, following oral administrations of Rooibos tea extract. Thus, our findings suggested that Rooibos tea extract may facilitate the antigen-specific antibody production through selective augmentation of IL-2 generation both in vitro and in vivo. Collectively, Rooibos tea intake may be of value in prophylaxis of the diseases involving a severe defect in Th1 immune response such as cancer, allergy, AIDS, and other infections.

収録刊行物

被引用文献 (4)*注記

もっと見る

参考文献 (42)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ